Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 29, 1997

View Archived Issues

FDA wants stronger warning labels for fen/phen

Review of fenfluramines points to neurotoxicity

Disappointing phase III trial results with interferon gamma for atopic dermatitis

Faulding's generic acyclovir receives FDA approval

Mayo Clinic, Wyeth-Ayerst plan fen/phen study

DIAMOND CHF study results reported

FDA approves Gensia's injectable acyclovir

Seven studies published on Emdogain

SYST-EUR trial results presented

Panretin trial in KS halted early

Notice of allowance for LHRH vaccine patent

FKBP12 inhibitors in the pipeline at Guilford

Innothera discloses more agents for venous function deficiency

P&U cephem derivatives for inhibiting HLE

Stromelysin inhibitors: New approach to treating arthritis?

Kos Pharmaceuticals: Q4 and year-end highlights

Cortecs granted patent for Flustat

Novopharm Biotech, Genesys Pharma receive approval to amalgamate

Pharos receives patent for novel method of controlling and treating inflammation

Inex: Q2 1997 highlights

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...